MK2 depletion in P53-deficient cells suppressed Cdc25A-mediated S phase arrest following cisplatin treatment and Cdc25B-mediated G2/M arrest following doxorubicin exposure, resulting in mitotic catastrophe and tumor regression in vivo [92]. This evidence concerns the gene TP53 and neoplasm.